Cosmo N.V. (SWX:CMHC)

Market Cap	928.29M -7.3%
Revenue (ttm)	94.79M -43.7%
Net Income	-5.86M
EPS	-0.36
Shares Out	17.19M
PE Ratio	n/a
Forward PE	869.07
Dividend	1.97 (3.54%)
Ex-Dividend Date	Apr 24, 2026

Volume	46,321
Open	54.30
Previous Close	54.00
Day's Range	54.30 - 57.00
52-Week Range	51.70 - 129.40
Beta	1.47
Analysts	Strong Buy
Price Target	123.95 (+122.53%)
Est. Earnings	Oct 23, 2026

About Cosmo

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 365
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: CMHC

Financial Performance

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for CMHC stock is "Strong Buy." The 12-month stock price target is CHF 123.95, which is an increase of 122.53% from the latest price.

Price Target

CHF 123.95

(122.53% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 29, 2026

Data Sources Report a data error